Comparative Pharmacology
Head-to-head clinical analysis: EQUAGESIC versus EQUANIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUAGESIC versus EQUANIL.
EQUAGESIC vs EQUANIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
Gamma-aminobutyric acid (GABA) receptor positive allosteric modulator; increases frequency of chloride channel opening, potentiating inhibitory neurotransmission.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
400 mg orally 3-4 times daily; maximum 2400 mg/day. Alternatively, 200 mg orally 3-4 times daily for mild anxiety.
None Documented
None Documented
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Terminal elimination half-life is 6-20 hours (mean 10 hours). In hepatic cirrhosis, half-life may be prolonged to 24-36 hours due to impaired clearance.
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Primarily renal excretion of conjugated metabolites (inactive); approximately 90% of a dose is excreted in urine, with less than 10% in feces. Less than 5% is excreted unchanged.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic